[Sex-related differences in the treatment of coronary artery disease]

Antonino Di Franco1, Giorgia Bonalumi2, Mario Gaudino1

  • 1Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.

Giornale Italiano Di Cardiologia (2006)
|October 27, 2022
PubMed

Insights

Investigating sex differences in coronary artery disease treatment outcomes is crucial. Current risk scores and treatments may not adequately address women

Area of Science:

  • Cardiology and cardiovascular disease research.
  • Sex-based differences in medical treatment outcomes.
  • Clinical decision-making in cardiovascular interventions.

Background:

  • Differential outcomes between men and women in coronary artery disease (CAD) treatment require further investigation.
  • Existing cardiovascular risk scores are often based on male populations, potentially limiting their accuracy for women.
  • There's a lack of sex-specific recommendations for diagnosing and treating CAD.

Approach:

  • Reviewing and synthesizing the latest scientific evidence on CAD treatment outcomes in men and women.
  • Analyzing outcomes based on percutaneous coronary intervention (PCI) and surgical revascularization strategies.
  • Highlighting the importance of considering sex-based anatomical, functional, and risk factor differences.

Key Points:

  • Sex-based differences in anatomical features, functional characteristics, and risk factors influence CAD treatment strategies.
  • Current risk stratification tools may not accurately predict cardiovascular risk in women.
  • The need for sex-specific diagnostic and therapeutic guidelines in managing CAD is increasingly recognized.

Conclusions:

  • Evidence suggests that sex is a significant factor in CAD treatment outcomes.
  • Therapeutic strategies for CAD should be individualized, considering sex-specific characteristics.
  • Further research is needed to develop and validate sex-specific approaches for CAD management.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
23
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
627
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
16
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
229